Trial Profile
Phase II trial of AVN 322 in patients with Alzheimer's disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2013
Price :
$35
*
At a glance
- Drugs AVN 322 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Avineuro Pharmaceuticals
- 27 Jun 2013 Status changed from planning to discontinued.
- 09 Feb 2010 New trial record